Spyre Therapeutics, Inc. announced poster presentations at Digestive Disease Week (DDW) 2025, including up to eight months of follow-up data from its ongoing Phase 1 trial of SPY001. The extended data continue to support SPY001's potential best-in-class profile for inflammatory bowel disease (IBD).
Pharmacokinetic (PK) data up to eight months showed SPY001's half-life is approximately 80 days, more than three times that of vedolizumab. This prolonged half-life supports potential quarterly or biannual subcutaneous maintenance dosing in a single autoinjector.
Pharmacodynamic (PD) data up to eight months demonstrated that a single dose of SPY001 resulted in rapid and sustained saturation of α4β7 receptors at expected Phase 2 trough concentrations. The company remains on track to initiate its planned platform Phase 2 trial in mid-2025, which will include SPY001.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.